Credit: Milestone Pharmaceuticals Cardamyst is supplied as a carton of 2 disposable nasal spray devices, each delivering 2 sprays containing a total of 70mg of etripamil. Cardamyst is expected to be ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved a rapid-acting nasal spray for the treatment of acute symptomatic paroxysmal supraventricular ...

The investigational intranasal L-type calcium channel blocker etripamil continues to be well tolerated and effective for self-treating recurrent episodes of paroxysmal supraventricular tachycardia ...

Milestone Pharmaceuticals (NASDAQ:MIST) shares jumped roughly 35% after the U.S. Food and Drug Administration approved CARDAMYST, the first nasal spray that patients can self-administer to treat ...

CARDAMYST nasal spray is a novel and rapid-acting calcium channel blocker delivered when needed to treat often highly symptomatic and unpredictable episodes of PSVT. With CARDAMYST, adults with PSVT ...

(RTTNews) - Milestone Pharmaceuticals Inc. (MIST) has received FDA approval for its first commercial product, CARDAMYST nasal spray, for the conversion of acute symptomatic episodes of paroxysmal ...

Investing.com -- Milestone Pharmaceuticals (NASDAQ:MIST) stock surged 35% after the company received FDA approval for CARDAMYST, the first self-administered nasal spray for adults with paroxysmal ...

MONTREAL and CHARLOTTE, N.C., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) today announced plans to resubmit the New Drug Application (NDA) for etripamil to the ...

MONTREAL and CHARLOTTE, N.C., March 28, 2025 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) today announced the U.S. Food and Drug Administration (FDA) issued a Complete Response ...

A nasal spray that delivers a short-acting calcium-channel blocker (CCB), envisioned as a self-treatment alternative to a pill-in-the-pocket strategy for managing bouts of paroxysmal supraventricular ...